Skip to main content

Table 4 Association of various characteristics with the initial ART discontinuation in treatment-naive patients starting therapy between Jan 2011 and Feb 2017 using competing risk models and cause-specific Cox models

From: Trends and factors associated with modification or discontinuation of the initial antiretroviral regimen during the first year of treatment in the Turkish HIV-TR Cohort, 2011–2017

Characteristic

Subdistribution Hazard Model

Cox Proportional Hazard Model

Univariate analysis

Multivariable analysis

Multivariable analysis

Univariate analysis

Multivariable analysis

Multivariable analysis

 

Model 1

Model 2

 

Model 1

Model 2

SHR (95% Cl)

P value

SHR (95% Cl)

P-value

SHR (95% Cl)

P-value

HR(95% Cl)

P-value

HR (95% Cl)

P-value

HR (95% Cl)

P-value

Age (years)

 ≤45

1.0*

 

1.0*

 

1.0*

 

1.0*

 

1.0*

 

1.0*

 

 >45

1.3 (1.1-1.7)

0.014

1.3 (1.0-1.6)

0.054

1.3 (1.0-1.6)

0.060

1.3 (1.1-1.7)

0.015

1.3 (1.0-1.6)

0.061

1.2 (1.0-1.6)

0.051

Sex

 Male

1.0*

 

1.0*

 

1.0*

 

1.0*

 

1.0*

 

1.0*

 

 Female

1.3 (1.0-1.7)

0.055

1.2 (0.9-1.6)

0.230

1.1 (0.8-1.4)

0.590

1.3 (1.0-1.8)

0.050

1.2 (0.9-1.6)

0.202

1.1 (0.8-1.5)

0.634

Transmission mode

 MSM/Bisexual

1.0*

     

1.0*

     

 Heterosexual

1.1 (0.9-1.4)

0.520

    

1.1 (0.9-1.4)

0.432

    

 IVDU

1.9 (0.3-13.7)

0.530

    

1.9 (0.3-13.4)

0.532

    

 Other

1.7 (0.9-3.0)

0.100

    

1.5 (0.7-2.9)

0.280

    

 Unknown

1.1 (0.7–1.6)

0.750

    

1.1 (0.7–1.7)

0.649

    

Viral load (copies/mm3)

< 100.000

1.0*

     

1.0*

     

≥ 100.000

1.1 (0.9–1.4)

0.240

    

1.1 (0.9–1.4)

0.331

    

AIDS diagnosis

 Category C or CD4 < 200 cells/mm3

1.4 (1.1–-1.8)

0.003

1.2 (1.0–1.5)

0.110

1.2 (0.9–1.5)

0.200

1.4 (1.1–1.8)

0.001

1.3 (1.0–1.6)

0.056

1.2 (1.0–1.5)

0.136

Initiation era

 2011–2014

1.0*

 

1.0*

 

1.0*

 

1.0*

 

1.0*

 

1.0*

 

 2015–2017(Feb)

0.8 (0.6–1.0)

0.021

0.5 (0.4–0.7)

<.0001

0.4 (0.3–0.6)

<.0001

0.8 (0.6–1.0)

0.023

0.6 (0.4–0.9)

<.0001

0.5 (0.3–0.6)

<.0001

Class

 InSTI

1.0*

 

1.0*

   

1.0*

 

1.0*

   

 NNRTI

2.6 (1.9–3.6)

<.0001

4.4 (3.0–6.6)

<.0001

  

2.6 (1.9–3.6)

<.0001

4.4 (3.0–6.4)

<.0001

  

 PI

3.2 (2.4–4.2)

<.0001

4.4 (3.2–6.1)

<.0001

  

3.2 (2.4–4.2)

<.0001

4.3 (3.1–6.0)

<.0001

  

Regimen

 EVG/c/TDF/FTC

1.0*

   

1.0*

 

1.0*

   

1.0*

 

 EFV/TDF/FTC

2.5 (1.7–3.7)

<.001

  

4.8 (3.1–7.5)

<.0001

2.5 (1.8–3.7)

<.0001

  

4.8 (3.1–7.3)

<.0001

 LPV/r/TDF/FTC

3.0 (2.1–4.3)

<.001

  

4.9 (3.3–7.3)

<.0001

3.1 (2.1–4.4)

<.0001

  

4.9 (3.3–7.3)

<.0001

 DTG/TDF/FTC

0.5 (0.2–1.0)

0.048

  

0.5 (0.2–0.9)

0.032

0.5 (0.3–1.0)

0.053

  

0.5 (0.2–0.9)

0.054

 DRV/r/TDF/FTC

2.3 (1.4–3.6)

<.001

  

2.8 (1.8–4.5)

<.0001

2.3 (1.4–3.6)

0.001

  

2.8 (1.8–4.5)

<.0001

 RAL/TDF/FTC

3.4 (1.8–6.6)

<.001

  

3.5 (1.8–6.7)

<.0001

3.4 (1.8–6.6)

<.0001

  

3.5 (1.8–6.7)

<.0001

 LPV/r/ZDV/3TC

9.0 (5.3–15.2)

<.001

  

15.5 (8.5–28.4)

<.0001

9.5 (5.6–16.2)

<.0001

  

16.2 (8.9–29.4)

<.0001

 EFV/ZDV/3TC

3.3 (1.5–7.3)

0.003

  

6.6 (2.8–15.3)

<.0001

3.3 (1.5–7.4)

0.004

  

6.4 (2.8–15.1)

<.0001

 Other

1.6 (0.6–4.0)

0.350

  

1.8 (0.7–4.6)

0.240

1.6 (0.6–4.1)

0.323

  

1.8 (0.7–4.5)

0.228

  1. sHR subdistribution hazard ratio, HR hazard ratio, CI confidence interval, 3TC lamivudine, DRV darunavir, DTG dolutegravir, EFV efavirenz; EVG/c elvitegravir/cobicistat, FTC emtricitabine, InSTI integrase strand transfer inhibitor, IDU injection drug user, LPV lopinavir, MSM men who have sex with men, NNRTI non-nucleoside reverse transcriptase inhibitor, PI protease inhibitor, RAL raltegravir, r ritonavir, TDF tenofovir disoproxil fumarate, ZDV zidovudine
  2. Model 1 includes common displayed variables and drug classes (excluding InSTI/PI)
  3. Model 2 includes common displayed variables and most common regimens
  4. *is reference category
Back to article page

AIDS Research and Therapy

ISSN: 1742-6405

Contact us